Biotech investor Martin Shkreli’s trial on securities fraud charges has been set for June 26, 2017, according to media reports Thursday. The trial date was set by a U.S. judge in a Brooklyn court at a hearing. Shkreli was arrested last December and charged with securities and wire fraud in relation to a company called Retrophin that he was head of and a separate hedge fund he was running. His then lawyer Evan Greebel is also facing fraud charges. Shkreli had become a controversial figure in the U.S. before his arrest for his practice of buying drugs and immediately hiking their prices by significant amounts. In June, prosecutors added new charges against Shkreli and Greebel, both of whom have pleaded not guilty.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.